Anthony Stack, DO retweeted
Pick any medical specialty other than your own. Who’s the most famous physician in it? You probably can’t name one.
Almost none of us will be known outside our field, and even those who achieve real professional fame are mostly forgotten within a few decades.
Fame is a poor reason to devote your life to medicine. The work itself matters more: caring for patients, discovering new knowledge, and teaching the next generation.
Replying to @HenrychihangFu1
Hard to see the niche for Pola-R-GemOx. Bridging to CAR-T in GCB patients who received 1L R-CHOP (ie pola naive) may be the one place it fits - but that isn’t what this trial tested. Maybe the better question: should beating GemOx still count as success?
1
41
Anthony Stack, DO retweeted
A persistent, itchy rash that doesn't improve with treatment could be more than eczema or psoriasis.
Anthony Stack, MD, of Fox Chase Cancer Center explains the signs of cutaneous lymphoma, a rare cancer that often goes undiagnosed for years: bit.ly/4vPApfO
Anthony Stack, DO retweeted
#ASCO26 #AML #leusm
Does venetoclax duration matter in frontline HMA+Ven for AML?
Poster: In a @MayoCancerCare analysis of 540 newly diagnosed AML patients, outcomes were driven primarily by disease biology, not venetoclax duration. Led by Dr. Naseema Gangat 👏👏👏
🔹 Similar OS across 7-, 14-, 21-, and 28-day schedules
🔹 Comparable outcomes within ELN 2024 and Mayo genetic risk groups
🔹 Higher early mortality with shorter durations likely reflected selection of frailer patients
🔹 In ELN high-risk AML, 14-day venetoclax was associated with inferior survival compared with 21- and 28-day schedules
Take-home: Venetoclax duration should be individualized based on genetics, response, cytopenias, and patient fitness rather than a one-size-fits-all approach.
🚨 NEW PUBLICATION 🚨
doi.org/10.3389/fimmu.2026.1…
CAR-T Exhaustion = A Major Barrier to Durable Remission 🧬⚡
CAR-T cells are powerful, but even engineered T cells can become exhausted.
Relapse after CAR-T is not always just antigen escape. Sometimes the engine burns out.
Key biology of CAR-T exhaustion:
• Tonic signaling before tumor contact
• CD28 vs 4-1BB = speed vs persistence
• PD-1/TIM-3/LAG-3/TIGIT = clues, not the whole story
• TOX/NR4A/BATF help lock in dysfunction
• The TME can starve, suppress, and reprogram CAR-T cells
What it looks like:
• poor expansion
• loss of persistence
• impaired tumor killing
• relapse after initial response
🧪 Next-gen strategies aim to keep CAR-T cells functional longer with smarter CARs, gene editing, armored CARs, rational combinations and more.
CAR-T failure is not one problem.
It’s a systems biology problem.
Check out our new @FrontImmunol review for more:
doi.org/10.3389/fimmu.2026.1…
#CARTcells #Lymphoma #Immunotherapy #CellTherapy #HemeTwitter
1
2
158
Anthony Stack, DO retweeted
Anthony Stack, DO retweeted
Original Article: Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (MajesTEC-3 phase 3 trial) nej.md/4431DUD
#ASH25 | @ASH_hematology
Anthony Stack, DO retweeted
Anthony Stack, DO retweeted
This prospective international analysis demonstrated a real-world t(11;14) detection rate of 22.1% in patients with MM. Read in Blood Advances: ow.ly/25aM50XyeiT #MultipleMyeloma #BloodAdvances
Anthony Stack, DO retweeted
Guidelines for T cell nomenclature bit.ly/48258LX
Anthony Stack, DO retweeted
All the major risk stratification models for myeloma, MGUS, SMM, WM, amyloid in one place!
Open Access! @LeukemiaJnl
@ZanwarSaurabh nature.com/articles/s41375-0…
Anthony Stack, DO retweeted
✨ IgG4-Related Disease: Emerging Insights
One of the best #IgG4RD articles I’ve come across! Published in Allergy (2025) 🧾
🔹 4 Clinical Phenotypes
Pancreato-biliary | Retroperitoneal/Aortitis | Head & Neck | Mikulicz/Systemic
🔹 Key Biomarkers
Plasmablasts, galectin-3, CCL18 🔬
Serum IgG4 → supportive, not specific 🚫
🔹 Genetics & Pathogenesis
HLA-DRB1, FCGR2B, IKZF1 variants 🧬
CD4⁺ CTLs, Tfh2/BATF⁺ Tfh, ILC2s, M2 macrophages → fibrosis & immune dysregulation
Microbiome: ↑Streptococcus/Clostridium, ↓butyrate producers
🔹 Therapeutics
Steroids = fast, but relapse 40% ⚠️
Rituximab = effective 💉
Inebilizumab (FDA 2025) → 87% flare reduction 🚀
Pipeline: BTK, JAKi, dupilumab, daratumumab
🔹 Future Directions
Multi-omics, novel biomarkers, fibrosis pathways (IL-33/ST2, IL-6/IL-6R)
➡️ Towards precision, steroid-sparing therapy
👉 IgG4-RD = fibrosis + immune dysregulation + B/T cell crosstalk
Truly a landmark review shaping tomorrow’s #PrecisionMedicine ✨
DOI: 10.1111/all.16686
#IgG4RD #Allergy #Immunology #Rheumatology #Fibrosis
Anthony Stack, DO retweeted
Just out in the New England Journal of Medicine!
Our comprehensive Review on MGUS: Monoclonal Gammopathy of Undetermined Significance @NEJM nejm.org/doi/full/10.1056/NE…
5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and Figures. Bookmark!
How to test and manage patients. Who needs bone marrow exams and scans. It’s all in here!
MGUS is important not just because it’s a precursor to multiple myeloma. It causes a lot of other problems. Learn all about MGUS, and the various terms you hear MGCS, MGRS etc. in this Review
@myelomaMD and I have tried to keep every sentence in this Review simple and easy to follow. #MGUSVR
Anthony Stack, DO retweeted
Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma ashpublications.org/blood/ar…


































